Posted by Michael Wonder on 14 Dec 2025
Milestone receives FDA approval of Cardamyst (etripamil) as first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia
12 December 2025 - First FDA approved treatment in 30+ years for more than 2 million Americans with paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals today announced that the US FDA approved its first commercial product, Cardamyst (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults.
